| Literature DB >> 14513688 |
Abstract
XOMA is developing ING-1, a human engineered immunoglobulin G1 antibody, as a potential treatment for carcinoma and solid tumors. In November 2000, ING-1 entered phase I trials in the US and by February 2002, phase I/II trials had been initiated.Entities:
Mesh：
Substances：
Year: 2003 PMID： 14513688
Source DB: PubMed Journal: Curr Opin Mol Ther ISSN： 1464-8431